Fusion and clinical outcomes of lumbar interbody fusion for low-grade isthmic spondylolisthesis

Introduction: Low-grade isthmic spondylolisthesis (ISPL) is generally treated by circumferential fusion with interbody graft, although there is no consensus on technique.Hypothesis: The various interbody fusion strategies provide satisfactory fusion rates and clinical results. Methods: A multicenter retrospective study analyzed lumbar interbody fusion for low-grade ISPL per-formed between March 2016 and March 2019. Techniques comprised: circumferential fusion on a posterior or a transforaminal approach (PLIF, TLIF: n = 57), combined anterior (ALIF) + posterolateral fusion (ALIF + PLF: n = 60), and ALIF + percutaneous posterior fixation (ALIF + PPF: n = 55). Function was assessed on a lumbar and a radicular visual analog scale (AVS-L, VAS-R), Oswestry Disability Index (ODI) and Short Form 12 (SF12).Results: Among the 129 patients, 85.3% showed fusion (Lenke 1 or 2), with no significant differences between the ALIF-PLF or ALIF-PPF groups and the PLIF or TLIF groups (p = 0.3). Likewise, there was no difference in fusion rates between the ALIF-PPF and ALIF-PLF subgroups (p = 0.28). VAS-L (p < 0.001) and VAS-R (p < 0.0001), ODI (p < 0.001) and SF12 physical (PCS) (p < 0.01) and mental component sores (MCS) (p < 0.001) all showed significant improvement at 12 months. Combined approaches provided greater clinical efficacy than TLIF or PLIF for lumbar (p < 0.0001) and radicular pain (p < 0.05), ODI (p < 0.0001) and SF12 PCS (p < 0.01). At 12 months, there was no clinical difference between the ALIF-PPF and ALIF-PLF subgroups. However, patents with interbody non-union (Lenke 3 or 4) had lower SF12 PCS scores (p < 0.004) and VAS-L ratings (p < 0.001) than Lenke 1-2 patients.Conclusion: Low-grade ISPL treated by circumferential arthrodesis and interbody graft showed 85.3% consolidation at 2 years, with equivalent outcomes between anterior and posterior techniques. Successful fusion was associated with better clinical results. Level of evidence: IV.(c) 2022 Published by Elsevier Masson SAS.